En Fr

Season’s Greetings from Plants Not Pills!

Season's Greetings from Plants Not Pills!

Season’s Greetings from Plants Not Pills!

With the holiday season approaching, Plants Not Pills wants to make sure you are giving yourself the gift of amazing cannabis. This is why we’ve put together a short holiday guide below featuring all the newest, stand out strains that our patients and staff have been raving about.

If you or someone you know is not yet licensed, please note that Plants Not Pills is currently offering a $25 dollar discount on its admin fees. Simply register with the holiday promo code HAPPY16 and we will automatically subtract $25 off any admin fees associated with licensing.

If you feel like trying any of the strains below, please contact patientservices@nlphysicians.com or call 226-456-1497 and we will help you add or switch your Licensed Producer free of charge.

From all of us at Plants Not Pills, we wish you the best of health and a very Happy Holiday Season!

Buddha Haze
(THC: 18%, 0.4%)
CannTrust
$10.50/gram This strong sativa, THC- dominant strain is getting great reviews as a second-to-none sleep aid.
Learn More
 

Platinum Mint Cookies
(THC: 17-20%, CBD: 0.1%)
D.S. & FITZ
$12.00/gram Platinum Mint Cookies is an OG Kush and Durban Poison premium hybrid that takes its users to euphoria’s top floor.
Learn More
Blueberry Kush
(THC: 16%, CBD: 0.4%)
CannTrust
$10.50/gram A potent Indica for those looking for a rich body buzz and serious pain relief. Serious relaxation guaranteed!
Learn More
Great Bear
(THC: 16%, CBD: 0.4%)
Aphria
$5.99/gramCurrently Aphria’s strain of the month, Great Bear is an effective and economical sativa dominant, high THC strain… 
Learn More
Embrace 
(THC: 6.1%, CBD: 9.8%)
D.S. & FITZ
$8.00/gram A Sativa-dominant strain, Embrace is known for its ability to relax without sedation, to relieve without …
Learn More
Wilbur
(THC: 2.5%, CBD: 5.88%)
Aphria
$7.20/gramA vigorous THC/CBD sativa dominant strain that is a perfect pick-me-up for the winter blues and also an effective strain for pain relief…
Learn More

Veterans Group ‘Marijuana for Trauma’ Responds to Cutbacks in the Updated Policy on Medical Marijuana Coverage for Veterans

correct-mft-banner

TORONTO, ONTARIO–(Marketwired – Nov. 22, 2016) – Canada House Wellness Group Inc. (formerly Abba Medix Group Inc.) (“Canada House“) or the (“Company“) (CSE:CHV)(CSE:CHV.CN)(CNSX:CHV), the parent company of Marijuana for Trauma (“MFT“) is providing this update in response to the Government’s recently announced policy changes regarding medical marijuana coverage for veterans.

In response to Veterans Affairs Canada’s planned cutback of medical marijuana reimbursements to veterans, MFT has pledged to implement clinical programs and processes to help veterans to continue to receive their medically appropriate prescribed amount of medicine.

These changes, which suggest three grams per day to be the maximum reimbursable dose, contradict what thousands of veterans relying on cannabinoid therapy have found to be effective. In our view, appropriately prescribed dosage amounts, based on individual needs, drastically reduces or eliminates their dependence on many other more harmful prescription medications.

The proposed cutback, from ten to three grams daily, is to take effect May 21, 2017 and is “very disheartening to those who have served their country with the Canadian Armed Forces,” says MFT spokesperson and co-founder Mike Southwell, a veteran of 17 years as a military engineer. “A veteran patient consumes an average of six grams of medical marijuana daily and many lives have been restored with this therapy. As an added result, many families are healing and rebuilding their relationships. To compound matters, there is practically no veteran who can afford the gap in coverage that these changes and the associated costs expose them to” said Southwell.

Southwell notes that most veterans have reduced both their dependence on opiate-based medicines and clinical visits to health care professionals for PTSD and pain management, as a direct result of cannabinoid therapy. “This could represent a significant cost savings over prescription medications and with minimal side effects.” adds Southwell. “Veterans have become functioning and productive citizens once again, after being injured in the course of their military service. They are vitally interested in continuing their recovery from trauma. The government must reconsider.”

Without their appropriate allocation of medical marijuana, veterans are at risk of descending back into harmful and abusive forms of self-medication, predicts Andrew Brown, President of MFT Ontario and a 13-year veteran of the Canadian Forces. “Suicides could increase.” he warns. “Veteran Affairs Canada’s arbitrary decision appears to be more of a “knee jerk reaction”, while at the same time, seemingly ignoring data surrounding the decrease in pharmaceutical complications and related medical expenses. We spare no costs whatsoever in rescuing even one soldier from the battlefield when they are missing, wounded or trapped. When we come home injured, after having served our country, does the value of our lives decrease?”

The bedrock of MFT goes back to the founder’s vision of supporting all the needs of veterans in Canada.

MFT hereby commits to all veteran patients that we will do anything in our power to safeguard you from any adverse effect of this decision as we continue our mission to reach every veteran in need of this life-saving medicine.

Canada House Wellness Inc.

Canada House is the parent company of MFT, The Longevity Project Corp., and Abba Medix Corp. The Company’s goal is to become a marketplace leader through strategic partnerships, mergers, and acquisitions to create a fully integrated medical marijuana marketplace. For more information please visit www.abbamedix.com, www.mftgroup.ca and www.plantsnotpills.ca.

Cautionary Statements Regarding Forward-Looking Information

Certain statements within this press release relating to the Company constitute “forward-looking statements”, within the meaning of applicable securities laws, including without limitation, statements regarding future estimates, business plans and/or objectives, sales programs, forecasts and projections, assumptions, expectations, and/or beliefs of future performance, are “forward-looking statements”. Such “forward-looking statements” involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements. Forward-looking statements include, but are not limited to, statements with respect to regulatory changes, timeliness of government approvals for the granting of permits and licenses, changes in medical marijuana prices, actual operating performance of facilities, competition and other risks affecting the Company in particular and the medical marijuana industry generally. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

  • Share on:

Cannabis and Sleep Disorders

Cannabis and Sleep Disorders

“The worst thing in the world is to try to sleep and not to”- F. Scott Fitzgerald

Ask most 100 year-olds about the secrets to their longevity and their answers are generally quite simple: good food and lots of sleep. In fact, a recent study by United Healthcare found that 70% of surveyed centenarians slept at least 8 hours a night.

But while we can all agree that a good night’s sleep is essential to wellbeing, millions of Canadians cannot sleep soundly through the night. According to a 2011 study by Laval University, 40% of adult Canadians suffer from sleep disorders such as restless leg syndrome, sleep apnia and chronic insomnia.

The Laval University findings seem to be reflected in the number of prescriptions for benzodiazepines and other sedatives in Canada, which rose to more than 20 million in 2011, up from 16.4 million in 2006, according to market research firm, IMS Brogan. This statistic is particularly worrying when taking into consideration a 2012 study led by Dr. Daniel Kripke, co-director of research at the Scripps Clinic. Kripke’s study concluded that the risk of developing lymphoma, lung, colon or prostate cancer associated with hypnotics was greater than the effect from smoking.

Since medical cannabis has been available in Canada to those with diagnosed sleep disorders, thousands of Canadians have opted to use this natural alternative to prescription sedatives.

The science behind the efficacy of medical cannabis on sleep habits has to do with TetraHydroCannabinol (THC), one of the principal compounds of the cannabis plant.

According to a 2013 study published in Frontiers in Psychiatry, “…Δ9-TetraHydroCannabinol (THC) stabilizes autonomic output during sleep, reduces spontaneous sleep-disordered breathing, and blocks serotonin-induced exacerbation of sleep apnea.”

Here at Plant Not Pills, we’ve had excellent feedback on a number of dried cannabis strains. One particular favourite is CannTrust’s Buddha Haze, a strong THC dominant (18%) sativa strain. Patients have also been enthusiastic about CannTrust’s 1:1 Cannabis Drops, a recent addition to their line of cannabis oils. For information about Buddha Haze or the 1:1 Cannabis Drops, call CannTrust directly at 1-855-794-2266.

For help with medical cannabis licensing or to sign up for a free medical cannabis consultation, please register on our website using the promo code PLANTS710.

  • Share on:

Cannabidiol (CBD) and Migraines

Blackboard with the chemical formula of CBD

For millions of people worldwide, a perceived change in light, altered vision, nausea and even hallucinations are just a few of the potential early onset symptoms of a migraine. Here is a brief overview of this neurological syndrome and how cannabidiol (CBD) can potentially alleviate the throbbing (and often excruciating) pain experienced by migraine sufferers.

What is a migraine?

According to the National Institute of Neurological Disorders and Stroke, “migraines are typically moderate to severe headaches that only affect one side of the head. They usually come on very suddenly and are described as throbbing or pounding headaches.”

Though the exact cause of migraines are still unknown, research published by the Migraine Research Foundation states that the cause of a migraine is due to a disorder in the nerve pathways and brain chemicals. Furthermore, studies have shown the disorder is linked to genes. Therefore, genetics play a factor.

According to statistics published in 2011 by Health Canada, approximately 2.7 million Canadians reported that they had been diagnosed with a migraine.

CBD Oil and Migraines

In 1990, researchers at the National Institute of Mental Health in Bethesda, MD, published the first study indicating that the brain contains cannabinoid receptors. In subsequent years, this group of receptors or portals came to be known as the endocannabinoid system, which according to research published in 2009 by the Department of Psychology at the University of Georgia, is “where the brain produces and processes endocannabinoids, the brain’s own cannabis-like substances. Endocannabinoids are thought to be responsible for regulating inflammation and pain sensation.” A study conducted by researchers at the Neuroscience Institute of Alicante, speaks about the effects of cannabidiol (CBD), a principal component of the cannabis plant and the second highest abundant in cannabinoids. According to the study, “cannabidiol has well-documented biological effects of potential therapeutic interest, such as anti-anxiety, anti-convulsive, anti-nausea, anti-inflammatory and anti-tumor properties.”

In 2010, the first study showing a link between the endocannabinoid system (ECS) and migraines was published by the IRCCS Neurological Institute. The findings corroborated the research from the Neuroscience Institute of Alicante. In addition, the IRCCS study suggested that “activation of ECS could represent a promising therapeutic tool for reducing both the physiological and inflammatory components of pain that are likely involved in migraine attacks.”

Since medical cannabis was first made accessible to Canadians in 2014, thousands of migraine sufferers have chosen high CBD medical cannabis strains as an alleviant for their migraine symptoms.

When it comes to CBD oil, our preferred licensed producer is CannTrust, which offers the ONLY pharmaceutically STANDARDIZED oral solution for patients who prefer not to smoke their medical cannabis. Migraine sufferers interested in trying CannTrust’s new CBD Drops should call 1-855-794-2266.

For help with medical cannabis licensing or to sign up for a free medical cannabis consultation, please register on our website using the promo code CBD710.

  • Share on:

Irritable Bowel Syndrome (IBS) and Medical Cannabis

ibs

By Dr. L Tennant, Ph.D

Irritable Bowel Syndrome (IBS) is an increasingly prevalent health issue in Canada, with over 5 million Canadians affected. It is a chronic, functional bowel disorder characterized by predominant diarrhea (IBS-D types), constipation (IBS-C types) or alternating patterns of both (IBS-M). Patients experience abdominal pain, cramping, bloating, gas and nausea with episodes that can last from days to months. In addition to uncomfortable and sometimes debilitating symptoms, many patients suffer anxiety and depression associated with the syndrome, which is known to exasperate the gastrointestinal symptoms.

Despite significant research efforts, the underlying physiological cause of IBS is not fully understood. Theories include previous GI infection, food poisoning, previous medication, hormonal or neurotransmitter imbalances. More recent research points to visceral sensitivity as the root cause of the painful symptoms associated with the syndrome, due to abnormal endogenous pain processing. In order to manage IBS, patients can be prescribed an array of medications including anti-spasmodic, anti-diarrheal or laxatives, pro-secretory agents (to increase the amount of fluid in the bowels), analgesics and antidepressants (at low doses for diarrhea and cramping, at higher doses for anxiety or depression relating to the disorder).

In lieu of or as an adjunct to these treatment regimens, many patients turn to medical cannabis for symptomatic relief.

Medical cannabis has been used by humans for centuries to alleviate abdominal pain and gastrointestinal dysfunction. The theory is that cannabis products contain active molecules that can interact directly with the receptors of the Endocannabinoid System (ECS), and provide relief by modulating it’s activity. The ECS is made up of families of receptors located throughout the brain and central nervous system of mammals that, through interaction with endogenous, natural or synthetic molecules, control a number of physiological processes including pain sensation, appetite, mood and memory. In the mammalian gut, the ECS produces endocannabinoid compounds “on demand” in order to auto-regulate and restore gut function and this regulation is mediated via the cannabinoid receptors. The cannabinoid molecules found in medical cannabis have been found to act in the same way as the ‘auto-regulatory’ or endogenous molecules and act thorough the same receptors. The most predominant and widely studied receptors of the ECS are CB1 and CB2.   CB1 receptors are expressed in the central nervous system and in the enteric nervous system of the gut whereas CB2 receptors are located on peripheral tissues and some types of immune cells.

In the gastrointestinal system, CB1 is involved in a number of important processes that are implicated in IBS including:

Gut motility and transit: Studies in several mammalian species have shown that activation of CB1 receptors slows down gut motility and inhibits muscle contraction transit, and that blocking CB1 receptors has the reverse effect, suggesting a role for cannabinoids with stimulating (agonist) or blocking (antagonist) effects for treatment of motility disorders. Furthermore, in a study of IBS-D patients, drobinol was shown to effectively reduce colonic motility and that this effect is mediated by the CB1 receptor.

Visceral pain relief: Studies in rodents demonstrated that treatment with certain cannabinoids had an analgesic effect on artificially induced visceral pain, again via stimulation of the CB1 receptor.

There is a growing body of data that suggests that subtle fluctuations in the levels of endocannabinoids in the gut are implicated in IBS. Studies in rodent models showed that low levels of endocannabinoids contribute to hyperalgesia and abdominal pain as well as changes in gastrointestinal mobility and that both were improved by increasing levels of endocannabinoids (endogenous or synthetic).

Furthermore, in humans, a study from the University of Calgary in 2013 showed a correlation between pain-related symptoms and the levels of endocannabinoids and endocannabinoid-like fatty acids in the blood of IBS-C and IBS-D patients.

Here at Plants Not Pills, we have received excellent patient feedback from two strains from the Peace Naturals Project. The first is Raphael, a high THC (18.7%) Indica dominant strain which many of our patients claim to be strong and to work well on cramping. This product also provides a little bit of appetite stimulation. Another strain offered by the Peace Naturals Project is Infiniti, which again works on the bloating/cramping feeling and pain that comes with the illness. For more information on either strain, please call the client care team at the Peace Naturals Project at 1-(888) 64-PEACE (73223)

For help with medical cannabis licensing or to sign up for a free medical cannabis consultation, please register on our website using the promo code RELIEF16 

  • Share on:

Why Cannabis Stimulates the Appetite

Top view of group of people having dinner together while sitting at the rustic wooden table

One of the most common effects of cannabis is appetite stimulation, which for some patients, may be one of cannabis’s most important benefits.

Hunger, Cannabis and the Brain

Inside the incredible hard wiring of our brains is an area called the hypothalamus that is tightly packed with neurons (cells that directly communicate messages to our nervous system). Every millisecond of every day, the hypothalamus is regulating the body’s basic processes, including heart rate, sleep cycles, temperature, sexual impulses and hunger by picking up signals from the organs and turning them into hormones.

In addition to neurons, the hypothalamus also contains cannabinoid receptors. According to findings published in the Diabetology & Metabolic Syndrome Journal, “The activation of central CB1 receptors, particularly in hypothalamic nuclei and in the limbic system, is involved in the regulation of feeding behavior, and especially in the control of the intake of palatable food.”

A 2012 study published in the science journal, Neuropharmacology confirms that, “THC increases sucrose palatability,” a probable explanation for why cannabis use often results in cravings for sweet foods.

For patients suffering from a dysfunctional hypothalamus as a result of head trauma or a genetic disorder, THC can be a game-changer. The same goes for cancer patients whose hypothalamus has been compromised by chemotherapy and resulted in extreme appetite/weight loss.

Appetite stimulation is vital to many patients’ health, but it must go hand-in-hand with an emphasis on nutrition. Though the body’s natural impulse may be to reach for sweets, it is essential that anyone with a compromised immune system stock up on nutrient-rich foods to promote to aid in the establishment of optimal health.

For patients in need of strains high in THC, we recommend the licensed producer, CannTrust. Not only does CannTrust carry a wide variety of affordable dried cannabis strains, but they also have THC Drops, THE ONLY pharmaceutical STANDARDIZED cannabis oil ideal for patients who prefer an alternative to smoking their medical cannabis. For questions about CannTrust’s THC strains or cannabis oils, feel free to call their customer service department at 1-855-794-2266.

For help with medical cannabis licensing or to sign up for a free medical cannabis consultation, please register on our website using the promo code PLANTS710.

  • Share on:

Medical Marijuana Coverage for Accident Victims

mmg-blog

Get help in accessing treatment funding for medical marijuana therapy!

As a result of recent precedent set by several high profile cases, victims of motor vehicle or workplace accidents in Canada are allowed to pursue medical marijuana coverage as part of their treatment plan.

Medical Marijuana Group (MMG) is a Plants Not Pills affiliate that manages medical marijuana for people affected by a personal injury. MMG aids its clients in obtaining 3rd party coverage, ensuring that all eligible candidates possess the following:

  • Legal representation
  • Medical records proving injuries stemming from accident
  • Prescription for medical marijuana from a physician
  • License to use medical marijuana

MMG offers access to funding options that enable uninterrupted treatment.

If you have suffered an accident and wish to pursue medical marijuana as a treatment option, email info@medmg.ca or call 519-890-9763 for more information.

  • Share on:

CBD Oil and Chronic Pain

correct-victoria

When a young Queen Victoria was prescribed a cannabis infusion for her severe menstrual cramps, she probably didn’t know the reason for her relief came from a component of the cannabis plant called cannabidiol (CBD).

Though the indomitable British monarch drank her ‘cannabis tinctures’ until she died at age 82, it would be several more decades before medical research would show the reason why CBD works so well for alleviating chronic pain.

In order to fully comprehend the link between CBD and chronic pain, it is important to understand the cannabis plant and its benefit to the human body.

The cannabis plant is made up of 85 different cannabinoids, many of which already exist in our bodies and are processed by endocannabinoid receptors or ‘portals’ found in our nerve endings. The cannabinoids processed by these receptors signal our brain to stimulate appetite, mood and pain sensation.

Cannabidiol (CBD) is one of the plant’s 113 chemical compounds and the second highest abundant in cannabinoids.

When we give our cannabinoid receptors additional cannabinoid-rich cannabidiol (CBD), we suppress the brain’s ability to process pain and hence get the relief that Queen Victoria and millions of other pain sufferers have enjoyed.

Why take CBD in oil form?

Generally, patients who take CBD oil do not feel the principal psychoactive component found in the cannabis plant called tetrahydrocannabinol (THC), the ingredient that causes the “high feeling” or hunger typically associated with marijuana.

Placing a few drops of CBD oil on your tongue or incorporating it into a healthy edible is the safest and most effective way to ingest cannabis.

When cannabis is vaporized or smoked, there is a very quick onset of effectiveness that only lasts for about 1-2 hours at peak levels. But when an edible oil is ingested, the peak levels of CBD concentration is not as high, though the concentration of CBD is at peak level for much longer – about 5-8 hours. This means that you can medicate less often while experiencing the same results.

Start accessing CBD oil from a wide variety of Licensed Producers by contacting Plants Not Pills at 1-844-473-6060 or click here to register.

 

Access to Cannabis for Medical Purposes Regulations (ACMPR)

Health Canada

By Kirsten O’Brien

The new Access to Cannabis for Medical Purposes Regulations (ACMPR) has sparked a flurry of questions and debate. Here is a basic breakdown of what the ACMPR entail and what they mean for Cannabis users across Canada.

On August 11, 2016 Health Canada announced that the current MMPR regulations will be replaced by the Access to Cannabis for Medical Purpose Regulations (ACMPR). These regulations include new guidelines for patients to be able to grow their own marijuana for medical purposes, or designate someone else to grow their cannabis for them. Patients will still be required to hold a valid prescription from a physician when growing their own medical marijuana, and purchase their plants/seeds through a Licensed Producer.

There have already been a lot of conversations going on between physicians and patients alike, wondering just what this will mean for patients in Canada. The only real difference is the allowance for patients to grow their own cannabis. The number of plants a patient will be allowed to posses will correlate directly with the number of grams per day that they are prescribed, as well as the location in which they are growing. Patients will still be required to have a valid medical marijuana prescription, no different than the prescriptions that are currently being issued.

Some important things to consider about these new regulations:

Cost

The savings for any patient are negligible. Medical marijuana can currently be purchased for as low as $2.75 per gram. The cost of growing can be much higher if a patient chooses to grow indoors as well.

Quality

Patients will be unable to have their strains tested which means that the exact amounts of THC/CBD will not be determinable. Licensed Producers are required to test their products for not only the THC/CBD content, but also contaminants. This may lead to a strain being much weaker than anticipated and/or full of contaminants, which will make it a less effective or even harmful medication.

Safety

There are several safety concerns with patients growing their own medical marijuana. Contaminants (i.e. mold), electrical fires, and an increased risk for burglary are all things that need to be considered when choosing to grow your own cannabis.

Physicians

Physicians need to be able to closely monitor their patients that are prescribed medical marijuana in order to work on future treatment plans. If a patient is only using home-grown marijuana, it will not be possible for their physician to provide any insight on future treatments. As the home-grown strains cannot be tested, it would be difficult for a doctor to determine exactly what a patient is ingesting and make future treatment recommendations.

Time

Growing marijuana can be a time-consuming endeavor. Not only does it take months for the plants to grow to maturity, they require a lot of care and a close eye in order to produce anything that could be consumed as medication. Maintenance of both the setup and the crop can take many hours per day to ensure that the medication does not become contaminated or completely useless to the patient.

It is important to keep in mind that until August 24, 2016 these new regulations are not in place, so the only legal way to obtain your medical marijuana is through one of the Licensed Producers. You are still required to have a valid prescription from a health care practitioner, and you still cannot legally purchase from any dispensary or compassion club.

If you would like information on licensing, Register Today at www.plantsnotpills.ca or contact us by email at info@plantsnotpill.ca

Marijuana For Trauma Grand Opening in Strathroy

MFT Poster Final copy

Marijuana For Trauma (MFT) is opening a brand new Wellness Centre in Strathroy, ON!

Join the Marijuana For Trauma (MFT) Strathroy team on Thursday, Aug. 4th for a free Pig Roast BBQ and afternoon filled with entertainment. The inauguration of the centre will also offer an opportunity to get information about Cannabis Therapy, Peer Support and Outreach Programs available through MFT for Veterans, First Responders, Military and Police.

Don’t miss a chance to connect with the MFT community and find out more about how they are helping thousands of Canadians treat PTSD, Chronic Pain and a variety of other health conditions.

Where: 40 Metcalfe St W, Strathroy, ON

When: Thursday, Aug. 4, 1-7 PM